Large‐scale cardiovascular outcomes studies have shown that SGLT2 inhibitors can reduce cardiovascular events, particularly hospitalization for heart failure in patients with T2DM and heart failure with reduced ejection fraction, with or without diabetes.6, 7, 8, 9. This evidence concerns the gene SLC5A2 and heart failure.